← brief for 2026-09-09 · Slowing decline

A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

Key takeaways

A large late-stage trial is starting to test a drug called elecoglipron against a placebo, a dummy pill, in adults with chronic kidney disease. Everyone in the study stays on dapagliflozin, an SGLT2 inhibitor already known to protect kidneys, plus their usual care. That design asks a useful question: does this drug add anything on top of the best treatment we have? People with and without type 2 diabetes can join. There are no results yet.

Who did this work

Run by AstraZeneca.
Sites: Research Site

Source

Trial · ClinicalTrials.gov, CKD recruiting · 2026-09-09
https://clinicaltrials.gov/study/NCT07753993